Athelas, Combinature merge with Singapore-based Merlion
Berlin/Geneva – The Singapore-based natural product specialist MerLion has bought two European firms. Together with the merger, the company will receive funding of a19.5 million. With Athelas, MerLion will have access to the company’s diVi antibiotic discovery platform.
“We wouldn’t have gotten such a large round in Germany”, said Dr. Harald Labischinski, former CEO of Combinature and now CSO of MerLion. Already in May, Labischinski announced the first closing of a a2.75 million – but a demand of a1.25 million, to satisfy his company’s capital needs, remained. After the merger, Combinature will be the drug discovery subsidiary of MerLion. Two antibiotic drug candidates will reach the clinic this year. MerLion CEO Tony Buss said that his company will be financed for the coming two years and anticipates an IPO within the next two years.